New laboratories were opened in GEROPHARM R&D centre to enhance
the development of biological products. The genetic engineering,
bioprocess development, and biochemistry laboratories were included in
the biotechnology unit.
The R&D centre was opened in the Neudorf SEZ in December 2011. In
2013 its area was 2-fold extended and amounted to more than 1.5 thousand
sq.m. The R&D centre specializes in the development of drugs on the
basis of a full-cycle (from molecules synthesis to finished dosage
form), tests and puts drugs in manufacturing, as well as arranges
preclinical and clinical studies.
The genetic engineering laboratory develops strains producing
recombinant proteins. The biochemistry laboratory is engaged in
development of pilot technologies for production of biological drugs
from natural sources of plant and animal origin. In addition, the
laboratory is engaged in the improvement of existing technologies and
participates in all biotechnology unit’s projects, for example, performs
processes of chemical modification of proteins. The bioprocess
development laboratory specializes in the optimisation of critical
points of the manufacturing process, performance of pilot tests of
production of recombinant proteins, their purification and quality
control in vitro. Following the studies experts make recommendations on
scaling of processes for their application in industrial production.
R&D is an important aspect of GEROPHARM’s activity; budget share
of R&D expenditure grows annually. Medical product development
projects, especially those involving biotechnological methods, are
long-term, as they require numerous studies, and are associated with
significant financial investments and their long payback period.
Currently, GEROPHARM carries out a total of more than 15 projects, including the development of drugs for diabetes treatment, as well as analogue insulins, nootropics, drugs for dementia and brain injury treatment, urological drugs.